Upadacitinib Nitroso impurity 1
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds.Upadacitinib is used to treat moderate to severely active rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis (a type of arthritis in the spine) with objective signs of swelling, moderate to severe ulcerative colitis, moderate to severe Crohn's disease.Upadacitinib Nitroso impurity 1 is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Upadacitinib Nitroso impurity 1 CAS NO:NA Chemically represented as (3S,4R)-3-Ethyl-4-(3-nitroso-3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide . Synchemia is the leading manufacturing and exporter of Upadacitinib Nitroso impurity 1. We supply Upadacitinib Nitroso impurity 1 with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0143891 |
| CAS No | NA |
| Mol.F. | C5H8N4O2S |
| Mol.Wt. | 188.21g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143892 |
| CAS No | NA |
| Mol.F. | C12H20N6O4S2 |
| Mol.Wt. | 376. 45 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143893 |
| CAS No | NA |
| Mol.F. | C12H17N5O3S3 |
| Mol.Wt. | 375.48 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143894 |
| CAS No | NA |
| Mol.F. | C12H17D3N6O3S2 |
| Mol.Wt. | 363.47g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143895 |
| CAS No | NA |
| Mol.F. | C23H21D6ClN8O5S |
| Mol.Wt. | 569.1 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143896 |
| CAS No | NA |
| Mol.F. | C24H29ClN8O5S |
| Mol.Wt. | 577.11 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143897 |
| CAS No | NA |
| Mol.F. | C24H29ClN8O5S |
| Mol.Wt. | 577.1 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143898 |
| CAS No | NA |
| Mol.F. | C24H29ClN8O5S |
| Mol.Wt. | 577.1 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143899 |
| CAS No | NA |
| Mol.F. | C8H8N2O3S |
| Mol.Wt. | 212.2 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143900 |
| CAS No | NA |
| Mol.F. | C7H7BrN2OS |
| Mol.Wt. | 247.11 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143901 |
| CAS No | NA |
| Mol.F. | C9H11N3O3S |
| Mol.Wt. | 241.3 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143902 |
| CAS No | NA |
| Mol.F. | C14H24N6O7 |
| Mol.Wt. | 340.38 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143903 |
| CAS No | NA |
| Mol.F. | C14H25N3O5 |
| Mol.Wt. | 315.37 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143904 |
| CAS No | NA |
| Mol.F. | C15H27N3O7S |
| Mol.Wt. | 393.46 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143905 |
| CAS No | NA |
| Mol.F. | C16H21ClN6O4 |
| Mol.Wt. | 396.83 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143906 |
| CAS No | NA |
| Mol.F. | C19H26N6O6S |
| Mol.Wt. | 466.51 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |